TD Cowen Picks Rhythm Pharmaceuticals as Top Biotech Stock
TD Cowen has identified Rhythm Pharmaceuticals as its leading recommendation in the biotechnology sector, assigning a price target of $130 per share. The firm highlighted Rhythm's Phase 2 clinical trial results for Imcivree in Prader‑Willi Syndrome, where six‑month data showed clinically meaningful improvement across all key endpoints. Patients experienced progressive weight loss with a mean body‑mass‑index reduction of 3 percent, and nine of eleven patients demonstrated meaningful hyperphagia reduction. TD Cowen views these outcomes as clearly supportive of Phase 3 development, underscoring the drug candidate’s commercial potential.